Depression, Bipolar
Conditions
Brief summary
The goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease. The main question it aims to answer is: Difference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depression, 6-item version (HDS-6) Participants will be randomized to treatment with either lithium or cariprazin. * Will meet for interview and ratings 4 times during study period. * In two meetings, there will be made blood samples and ECG. At one meeting also a Urine sample. * Will be contacted for telephone interviews at 6 occasions.
Detailed description
The primary aim is to investigate whether cariprazine is superior to lithium or vice versa in the acute treatment of patients with bipolar type 1 or 2 in a current depressive episode measured as change on the Hamilton Depression Scale, 6 item version (HDS-6) from baseline to 8 weeks of treatment. Secondarily, we aimed at comparing the two study medications on various other clinically relevant variables. These include depressive and manic symptomatology, sleep patterns, general well-being, cognitive function, social functioning and suicidal ideation.
Interventions
DRUGLithium
The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
DRUGCariprazine
The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
Sponsors
Aalborg University Hospital
Glostrup University Hospital, Copenhagen
Mental Health Department Odense, University Clinic
Psychiatric Center Copenhagen, Rigshospitalet
Psychiatric Hospital, Hillerod
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* A diagnosis of bipolar disorder, type 1 or type 2, and a current episode of depression according to DSM-5 * Severity of depression: A score of at least 21 on the self-reported Major Depression Inventory (MDI). * No start or dose increase of psychotropic medication (except for benzodiazepines and benzodiazepine-like drugs (zopiclone, zolpidem, and melatonin)) in the two weeks prior to inclusion. * No new start of formalized psychotherapy sessions, excluding psychoeducation, during the 4 weeks prior to inclusion. * Age criteria: Subjects must be at least 18 years old and below 65 at the time of randomization. * The duration of the current depressive episode must be between 4 and 52 weeks as judged by the investigator at the time of randomization. * Clinical uncertainty regarding which of the alternatives, cariprazine and lithium, would be the better choice in the specific case. * Female participants should be sterile or non-fertile or, in case of being fertile, they must have a negative pregnancy test AND use safe anticonception. * Signed document of informed consent.
Exclusion criteria
* Prior or ongoing acute treatment of a depressive episode lasting \> 14 days with either lithium or cariprazine as judged by the investigator. * ECT within the current depressive episode. * A score of MAS \> 6. * A diagnosis of dementia. * High risk of non-adherence at the investigator's discretion. * Not understanding the Danish language as judged by the investigator * Psychiatric coercion in the form of forced admission or detainment OR sentence to forensic psychiatric care. * Presence of clinically relevant delusions, hallucinations or other psychotic symptoms as judged by the investigator. * Suicidality according to C-SSRS with a positive response to question 4 or 5 or upon investigator's discretion. * Medical conditions like cancer, kidney failure, epilepsy, deep brain stimulation device, or other medical conditions interfering with study the outcome and safety as judged by investigator's discretion. * Current harmful use or dependency of alcohol or drugs according to DSM-5. * Known allergy to any of the substances in the study medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Hamilton Depressions scale, version 6 (HDS-6) | 8 weeks | The primary aim is to investigate whether cariprazine is superior to lithium or vice versa in the acute treatment of patients with bipolar type 1 or 2 in a current depressive episode measured as change on the Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference-in-difference for HDS-17 | Week 4 and 8 | Difference-in-differences for secondary continuous measures: Hamilton Depression Scale, 17 item version, HDS-17. (Values 0- 52, higher scores mean a worse outcome) |
| Difference-in-differences in HDS-6 for the PP 8 population | 8 weeks | Difference-in-differences (baseline to 8 weeks) in HDS-6 for the PP 8 population. Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome). |
| Between-groups difference in proportion of responders and remitters in HDS-6 Scores. | Week 4 and week 8 | Between-groups difference in proportion of responders and remitters at week 4 and 8 in HDS-6 scores. Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome). |
| Between-groups difference in proportion of responders and remitters | Week 4 and 8 | Between-groups difference in proportion of responders and remitters with response and remission defined by HDS-6 score without clinical relevant manic symptoms (MAS \<7) at planned or premature endpoint. Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome). |
| Between-groups difference in the proportion of patients with 'acceptable wellbeing' | up to 8 weeks | Between-groups difference in the proportion of patients with 'acceptable wellbeing', defined as the subject reporting ≥50 on the WHO-5 questionnaire at endpoint. WHO-five Well-being Index, WHO-5 (Values 0- 100, higher scores mean a better outcome). |
| Between-groups difference in proportion of switches to mania/hypomania. | up to 8 weeks | Between-groups difference in proportion of switches to mania/hypomania with or without mixed features, defined as mania/hypomania after DSM-5 or symptoms requiring treatment (switch or response occurring at any time in the study period) |
| Between-groups difference in "(switch to mania or hypomania) / (response) -ratio", | up to 8 weeks | Between-groups difference in "(switch to mania or hypomania) / (response) -ratio", defined as the number of subjects switching to mania or hypomania (as defined above) divided by the total number of responders, including those responders switching to mania |
| Between-group differences in reason for and time to all cause treatment discontinuation | up to 8 weeks | Between-group differences in reason for and time to all cause treatment discontinuation (lack of effect, lack of tolerability, lost to follow-up, or other cause). |
| Between-group difference in treatment compliance. | up to 8 weeks | Between-group difference in treatment compliance. Treatment compliance is defined as the proportion of received treatments out of the planned until drop-out or end of study. |
| Between-group difference in reasons for premature discontinuation | up to 8 weeks | Between-group difference for the ITT population in reasons for premature discontinuation |
| Difference-in-difference for MAS | Week 4 and 8 | Difference-in-differences for secondary continuous measures: MAS Bech-Rafaelsens Mania scale .(Values 0- 44, higher scores mean a worse outcome). |
| Difference-in-difference for MES | Week 4 and 8 | Difference-in-differences for secondary continuous measures: MES Bech-Rafaelsens Melancholia scale, MES .(Values 0- 44, higher scores mean a worse outcome). |
| Difference-in-differences for MADRS | Week 4 and 8 | Difference-in-differences for secondary continuous measures: MADRS Montgomery-Aaberg Depression Rating Scale, MADRS .(Values 0- 60, higher scores mean a worse outcome). |
| Difference-in-difference for YMRS | Week 4 and 8 | Difference-in-differences for secondary continuous measures:YMRS Young Mania Rating Scale, YMRS .(Values 0- 60, higher scores mean a worse outcome). |
| Difference-in-differences for ASRM-14 | Week 4 and 8 | Difference-in-differences for secondary continuous measures:ASRM-14 Altman Self-Rating Mania Scale-14, .(Values 0- 56, higher scores mean a worse outcome). |
| Difference-in-differences for MDI | Week 4 and 8 | Difference-in-differences for secondary continuous measures:MDI Major Depression Inventory, MDI (Values 0- 58, higher scores mean a worse outcome). |
| Difference-in-differences for WHO-5 questionnaire | Week 4 and 8 | Difference-in-differences for secondary continuous measures: WHO-5 questionnaire. WHO-five Well-beeing Index, WHO-5 (Values 0- 100, higher scores mean a better outcome). |
| Difference-in-difference for SCIP | Week 8 | Difference-in-differences for secondary continuous measures: SCIP Screen for Cognitive Impairment in Psychiatry, SCIP (Values 0- 64+, higher scores mean a better outcome) |
| Difference-in-difference for COBRA | Week 8 | Difference-in-differences for secondary continuous measures: COBRA Cognitive complaints in bipolar disorder Ratings assessment, COBRA, (Values 0- 48, higher scores mean a worse outcome). |
| Difference-in-difference for FAST | Week 4 and 8 | Difference-in-differences for secondary continuous measures: FAST Functioning Assessment Short Test, FAST (Values 0 - 72, higher scores mean a worse outcome). |
| Difference-in-difference for PSQI | Week 4 and 8 | Difference-in-differences for secondary continuous measures:PSQI PIttsburgh Sleep Quality Index, PSQI (Values 0 - 21, higher scores mean a worse outcome). |
| Difference-in-difference for CGI-S | Week 4 and 8 | Difference-in-differences for secondary continuous measures: CGI-S Clinical Global Impression Scale - Severity, CGI-S (Values 1 -7, higher scores mean a worse outcome). |
| Difference-in-difference for CGI-I | Week 4 and 8 | Difference-in-differences for secondary continuous measures:CGI-I Clinical Global Impression Scale - Global Improvement CGI- I (Values 1 -7, higher scores mean a worse outcome). |
| Difference-in-difference for C-SSRS | Week 4 and 8 | Difference-in-differences for secondary continuous measures: C-SSRS Columbia-Suicide Severity Rating Scale, C-SSRS (Values 1 - 5, higher scores mean a worse outcome). |
| Difference-in-difference for accumulated benzodiazepine dose | Up to 8 weeks | Difference-in-differences for secondary continuous measures: accumulated benzodiazepine dose as diazepam equivalents (DSKP) |
| Difference-in-difference for time to all-causes discontinuation | Up to 8 weeks | Difference-in-differences for secondary continuous measures: for time to all-causes discontinuation |
| Difference-in-difference for time to all-causes. all-causes study endpoint. | Up to 8 weeks | Difference-in-differences for secondary continuous measures: all-causes study endpoint. |
| Between-group difference in reasons for time to all cause discontinuation. | Up to 8 weeks | Between-group difference for the ITT population in reasons for time to all cause discontinuation. |
| Between-group difference in reasons for treatment expectation. | Up to 8 weeks | Between-group difference for the ITT population in reasons for treatment expectation. |
| Between-group difference in reasons for adverse events. | Up to 8 weeks | Between-group difference for the ITT population in reasons for adverse events. |
| Between-group difference in reasons for serious adverse events. | Up to 8 weeks | Between-group difference for the ITT population in reasons for serious adverse events. |
Countries
Denmark
Contacts
CONTACTSanne V. Hovgesen, MD
CONTACTSimon Johnsen, MsN
PRINCIPAL_INVESTIGATORRené E. Nielsen, Prof, MD,PhD
Psychiatry, Aalborg University Hospital
Outcome results
None listed